Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
JCV epidemiology in MS (JEMS)-Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients-Portuguese data.
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.
Individuals with neurological diseases are at increased risk of fractures within 180 days of admission to long-term care in Ontario.
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.
Network collapse and cognitive impairment in multiple sclerosis.
Apcdd1 stimulates oligodendrocyte differentiation after white matter injury.
Neurobiology: Myelin Goes Where the Action Is.
Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1.
The benefits and risks of alemtuzumab in multiple sclerosis.
Optic neuritis: From magnocellular to cognitive residual dysfunction.
Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil.
Neurologic indications for therapeutic plasma exchange: 2013 update.
Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI.
LINGO-1 regulates oligodendrocyte differentiation by inhibiting ErbB2 translocation and activation in lipid rafts.
The Importance of Nitric Oxide and Arginase in the Pathogenesis of Acute Neuroinflammation: Are Those Contra Players with the Same Direction?
Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies.
A rare association of tuberculous longitudinally extensive transverse myelitis (LETM) with brain tuberculoma.
Oligodendroglial Argonaute protein Ago2 associates with molecules of the Mbp mRNA localization machinery and is a downstream target of Fyn kinase.
[NLRP3 inflammasome and multiple sclerosis/EAE].
Adherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy.
Neurodegeneration: Active astrocytes drive inflammation.
Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies.
Porphyrin derivatives as potent and selective blockers of neuronal Kv1 channels.
Pages
« first
‹ previous
…
514
515
516
517
518
519
520
521
522
…
next ›
last »